A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates.

ABSTRACT: Vaccines against SARS-CoV-2 have been distributed at massive scale in developed countries, and have been effective at preventing COVID-19. Access to vaccines is limited, however, in low- and middle-income countries (LMICs) due to insufficient supply, high costs, and cold storage requirements. New vaccines that can be produced in existing manufacturing facilities in LMICs, can be manufactured at low cost, and use widely available, proven, safe adjuvants like alum, would improve global immunity against SARS-CoV-2. One such protein subunit vaccine is produced by the Serum Institute of India Pvt. Ltd. and is currently in clinical testing. Two protein components, the SARS-CoV-2 receptor binding domain (RBD) and hepatitis B surface antigen virus-like particles (VLPs), are each produced in yeast,

SUBMITTER: Dalvie NC 

PROVIDER: S-EPMC8288147 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature